X4 Pharmaceuticals, Inc
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(55,274) | $2,371 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,027 | 5,987 |
| Depreciation and amortization expense | 1,054 | 523 |
| Gain on sale of non-financial asset | — | (105,000) |
| Non-cash lease expense | 2,290 | 1,179 |
| Accretion of debt discount | 658 | 655 |
| Change in fair value of warrant liability | (12,796) | (4,596) |
| Other | 44 | (504) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 179 | — |
| Inventory | (1,263) | (2,445) |
| Prepaid expenses, other current and non-current assets and research and development incentive receivable | 862 | 1,197 |
| Accounts payable | (3,621) | (364) |
| Accrued expenses and other long-term liabilities | (4,190) | 3,832 |
| Deferred revenue | 1,381 | — |
| Lease liabilities | (1,442) | (741) |
| Net cash used in operating activities | (70,091) | (97,906) |
| Cash flows from investing activities: | ||
| Acquisition of intangible asset | (3,000) | (7,000) |
| Proceeds from sale of non-financial asset | — | 105,000 |
| Purchase of marketable securities | (61,487) | (34,354) |
| Sales and maturities of marketable securities | 55,792 | 12,250 |
| Acquisition of property and equipment | — | (285) |
| Net cash (used in) provided by investing activities | (8,695) | 75,611 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of shares of common stock under employee stock purchase plan | 46 | 159 |
| Proceed from borrowings under loan and security agreement | — | 20,000 |
| Proceeds from sale of shares of common stock, less issuance costs | 92,490 | — |
| Net cash provided by financing activities | 92,536 | 20,159 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 210 | 88 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,960 | (2,048) |
| Cash, cash equivalents and restricted cash at beginning of period | 56,475 | 100,248 |
| Cash, cash equivalents and restricted cash at end of period | $70,435 | $98,200 |
| Issuance costs not yet paid related to sale of shares of common stock and pre-funded warrants | $222 | $— |
| Acquisition of intangible assets included in accrued expenses | $— | $3,500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.